URGN
UroGen Pharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
URGN fundamentals
UroGen Pharma (URGN) expects to report earnings on Aug 12, 2025, with estimated revenue of 23.13M (YoY +6.10%), and EPS at -0.83 (YoY +8.79%).
Revenue estimate / YoY
23.13M
+6.10%
EPS estimate / YoY
-0.83
+8.79%
Report date
Aug 12, 2025
EPS
Revenue
Revenue & Expenses
URGN has released its 2025 Q1 earnings report, with revenue of 20.25M, reflecting a YoY change of 7.84%, and net profit of -43.84M, showing a YoY change of -35.80%. The Sankey diagram below clearly presents URGN's revenue sources and cost distribution.
Key Indicators
UroGen Pharma (URGN) key financial stats and ratios, covering profitability, financial health, and leverage.
UroGen Pharma (URGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
UroGen Pharma (URGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
UroGen Pharma (URGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does UroGen Pharma (URGN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track UroGen Pharma (URGN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
How were UroGen Pharma’s latest financial results overall?What guidance did UroGen Pharma’s management provide for the next earnings period? What is the market’s earnings forecast for UroGen Pharma next quarter?What does UroGen Pharma do and what are its main business segments?What factors drove the changes in UroGen Pharma’s revenue and profit?What were the key takeaways from UroGen Pharma’s earnings call?Did UroGen Pharma beat or miss consensus estimates last quarter?What is UroGen Pharma’s gross profit margin?